Key result
Baseline TMAO levels were not significantly associated with 30-day left ventricular systolic dysfunction in patients with a first anterior STEMI (median 1.9 μM vs 1.9 μM; p=0.46).
Why the study?
LVSD after STEMI confers poor outcomes, but the relationship between the gut metabolite trimethylamine N-oxide (TMAO) and LVSD after STEMI remains unclear.
Does baseline TMAO concentration predict 30-day left ventricular systolic dysfunction in patients with a first anterior STEMI after primary revascularization?
Observational (n=78)
Does baseline TMAO concentration predict 30-day left ventricular systolic dysfunction in patients with a first anterior STEMI after primary revascularization?
Baseline TMAO levels do not appear to predict 30-day left ventricular systolic dysfunction or infarct size in patients with a first anterior STEMI undergoing primary revascularization.
No TMAO-LVSD link tempers biomarker enthusiasm post-anterior STEMI; leaves open its prognostic value in broader cohorts.
Objective: Left ventricular systolic dysfunction (LVSD) after ST-segment elevation myocardial infarction (STEMI) is associated with poor outcome. Trimethylamine N-oxide (TMAO), a gut metabolite, is linked to cardiovascular diseases but its relationship with LVSD after STEMI remains unclear. The present study therefore aimed to investigate the relationship between TMAO and LVSD at 30 days after a first anterior STEMI. Methods: This was a sub-study from the OCTAMI (Optical Coherence Tomography Examination in Acute Myocardial Infarction) registry. Eligible patients were included in current study if they: (1) presented with a first anterior STEMI; (2) had available baseline TMAO concentration; (3) completed a cardiovascular magnetic resonance examination at 30 days after STEMI. LVSD was defined as left ventricular ejection fraction < 50%. Associations between TMAO and left ventricular ejection fraction, infarct size and left ventricular global strain were examined. Results: In total, 78 patients were included in final analysis. Overall, TMAO was moderately associated with peak cTnI ( r = 0.27, p = 0.01), age ( r = 0.34, p < 0.01), and estimated glomerular filtration rate ( r = −0.30, p < 0.01). At 30-day follow-up, 41 patients were in the LVSD group and 37 in the non-LVSD group. Baseline TMAO levels were not significantly different between the two groups (LVSD vs. non-LVSD: median 1.9 μM, 25−75th percentiles 1.5–3.3 μM vs. median 1.9 μM, 25−75th percentiles 1.5–2.7 μM; p = 0.46). Linear regression analyses showed that TMAO was not associated with left ventricular ejection fraction, infarct size or left ventricular global strain at 30 days (all p > 0.05). Conclusions: TMAO was not significantly correlated with 30-day LVSD in patients with a first anterior STEMI after primary revascularization. Clinical Trial Registration: www.ClinicalTrials.gov , identifier: NCT03593928.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2020) conducted an observational in First anterior ST-segment elevation myocardial infarction (STEMI) (n=78). Trimethylamine N-oxide (TMAO) vs. Non-LVSD group was evaluated on Left ventricular systolic dysfunction (LVSD) at 30 days (p=0.46). Baseline TMAO levels were not significantly associated with 30-day left ventricular systolic dysfunction in patients with a first anterior STEMI (median 1.9 μM vs 1.9 μM; p=0.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: